anti cgrp  (Cell Signaling Technology Inc)

Journal: Cell reports

Article Title: CGRP signaling links tumor-associated pain to immune evasion in oral squamous cell carcinoma

doi: 10.1016/j.celrep.2026.116994

Figure Lengend Snippet: (A and B) Representative images of OSCC tumor serial sections stained with either anti-Tubb3 (top, green outline), anti-TRPV1 (middle, red outline), or anti-CGRP (bottom, blue outline) from a patient with (A) and without (B) CGRPα + nerve innervation. Positive stains are indicated by red (TRPV1) or blue (CGRP) arrows. Tumor margins are indicated by a gray dashed line. Image magnification: 6× (left) and 40× (right). Scale bar: 200 μm. (C) Quantification of the percentage of total TRPV1 and CGRP-IR nerve area relative to total Tubb3-IR nerve area across tumor tissue sections from 23 patients with HNSCC. Density is reported as a stacked bar graph. (D) Quantification of the percentage of total CD8 T cell density per square millimeter. (E) Representative images of OSCC tumor serial sections with either a large nerve bundle and low anti-CD8 or small nerve presence and high anti-CD8 immunoreactivity. Scale bar: 150 μm. (F and G) Simple linear regressions were run between patient-reported pain, percentage of total CGRP-IR nerve area relative to total Tubb3-IR, and CD8 + T cell density relative to tumor area. Pain was measured by the FACT-HN additional question 12, “I have pain in my mouth, throat or neck” (FACT-HN10). The response to this question is rated on a scale of 0 (not at all) to 4 (very much). Spearman correlation r coefficients are listed on each graph; p < 0.05. Patient demographics are located in .

Article Snippet: Rabbit Anti-CGRP , Cell Signaling , 14959 S; RRID: AB_2798662.

Techniques: Staining

Journal: Cell reports

Article Title: CGRP signaling links tumor-associated pain to immune evasion in oral squamous cell carcinoma

doi: 10.1016/j.celrep.2026.116994

Figure Lengend Snippet: (A) Representative images of CGRP-IR in 300 μm optically cleared sagittal tongue sections from naive (left), MOC1 (middle), and MOC2 (right) tumor-bearing mice (10× magnification stitch, full focus z stack). Scale bar: 0.5 mm. (B) Representative images of co-staining with anti-CGRP and the pan-neuronal marker PGP9.5 in a 20 μm sagittal tongue section to demonstrate CGRP antibody specificity. Scale bar: 50 μm. (C) Representative images of neurite outgrowth in dissociated TG neurons in response to 24 h incubation in cell culture medium, MOC2 CM, or MOC2 medium + 1 μM anti-NGF monoclonal antibody (αNGF). A TG from one mouse was used for each treatment group, and the experiment was replicated five times ( n = 3 males, 2 females). For analysis, dissociated neurons were stained with anti-Tubb3 to visualize neurites and anti-NeuN to visualize cell bodies. Scale bar: 50 μm. (D–F) Integrative density of Tubb3 + neurites relative to the number of cell bodies in each field in response to medium and CM with or without αNGF; 12 areas of each chamber were imaged under 20× magnification, and analysis was completed within cell culture type (i.e., PEK, MOC1, and MOC2). Data are represented as mean ± SEM. One-way ANOVA; * p < 0.05, ** p < 0.01, *** p < 0.005, **** p < 0.001.

Article Snippet: Rabbit Anti-CGRP , Cell Signaling , 14959 S; RRID: AB_2798662.

Techniques: Staining, Marker, Incubation, Cell Culture

Journal: Cell reports

Article Title: CGRP signaling links tumor-associated pain to immune evasion in oral squamous cell carcinoma

doi: 10.1016/j.celrep.2026.116994

Figure Lengend Snippet: (A) Representative image of a coronal tongue section from non-tumor bearing mice 1 week following treatment with vehicle (top) or RTX (bottom), stained with anti-CGRP to demonstrate loss of CGRP-expressing fibers following RTX treatment. Scale bar: 100 μm. (B) Schematic of the trigeminal CGRP release assay. (C) CGRP protein quantification in TG isolated from mice 1 week after RTX injection into the tongue ( n = 5 F/group). Data are represented as mean ± SEM. Independent t test, ** p < 0.01. (D) Representative ATF3 staining of in TRPV1-IR neurons in the trigeminal mandibular branch in TG sections from vehicle- and RTX-treated mice. Scale bar: 50 μm. (E) Percentage of ATF3 + TRPV1 + neurons relative to total TRPV1 + neurons in the V3 region from across 9 sections/mouse of mice treated with vehicle or RTX ( n = 3 vehicle, 4 RTX). Tissue was collected 7 days after treatment. There was no difference in the number of TRPV1 neurons between groups. Data are represented as mean ± SEM. Independent t test, *** p < 0.005. (F) RTX treatment did not affect body weight compared to vehicle-treated mice. Change in body weight was calculated as (post-treatment day 7) – (weight on first day of treatment). Independent t test. (G) Representative H&E-stained 5 μm tongue sections from vehicle- and RTX-treated mice 21 days after treatment. The tumor boundary is indicated by a black dashed line. Scale bar: 1 mm. (H) MOC1 tumor volume between groups over time ( n = 5 F/group). Data are represented as mean ± SEM. two-way ANOVA, * p < 0.05. (I and J) Example dot plots and quantification of CD3 + T cell subtype, CD19 + B cells, and NK1.1 + natural killer (NK) cells between groups ( n = 3 F/group). Within-subtype t test comparison, **** p < 0.0001.

Article Snippet: Rabbit Anti-CGRP , Cell Signaling , 14959 S; RRID: AB_2798662.

Techniques: Staining, Expressing, Release Assay, Isolation, Injection, Comparison

Journal: bioRxiv

Article Title: Therapeutic interleukin-2 rewires skeletal-immune circuits to reverse postmenopausal bone loss

doi: 10.64898/2026.01.07.696511

Figure Lengend Snippet: (A) Schematics of the experiment. Rag1 -/- female mice received daily subcutaneous injections of low-dose IL-2 (30,000 I.U.) or PBS for 4 weeks, 4 weeks after ovariectomy or sham operation. (B) Representative 3D μCT images of the distal femurs. (C) Quantification of μCT images by BV/TV (bone volume per tissue volume), Tb.N (trabecular number), Tb.Sp (trabecular separation), and Tb.Th (trabecular thickness), n=7-10 per group, bar indicates mean, one-way ANOVA, ∗P<0.05, ∗∗P<0.01. (D) Representative histological images of bone sections stained with H&E (top), TRAP (middle), and anti-TRAP immunohistochemistry (bottom) to evaluate the abundance of osteoclasts on bone surface. (E) UMAP visualization of bone marrow innate lymphoid cell (ILC) subsets from scRNA-seq data (Left) with key genes identifying ILC2s and ILC1s/ILC3s subclusters (Right). (F) Split UMAP visualization showing the distribution of bone marrow ILCs in each treatment group. (G) Pie charts showing the ratio of ILC2s to ILC1s/ILC3s. (H-I) Representative flow cytometry plots (H) and the quantification of BM-ILC2s (Lin - CD45 + CD127 + ST2 + Sca-1 + ) in WT and Rag1 -/- mice (I) . (J) Volcano plot of bulk RNA-seq data from purified ILC2s showing differential expression between control and IL-2 treated groups. (K) GO Pathway enrichment analysis of ILC2s comparing OVX vs. OVX + IL-2 groups from scRNA-seq data. (L-M) FACS sorted bone marrow CD3 - B220 - NK1.1 - CD11b + cells and ILC2s (Lin - CD45 + CD127 + Sca-1 + ST2 + ) from WT, Il10 -/- , Calca -/- and Il10 -/- Calca -/- (DKO) were cocultured at indicated ratios, in the presence of 20 ng/ml M-CSF and 50 ng/ml RANKL. Osteoclast formation was evaluated by TRAP staining. Representative images (L) and quantification (M) of TRAP + multinucleated (nuclei > 3) cells. Representative of at least 3 independent experiments. Bar indicates mean, one-way ANOVA, ∗∗P<0.01, ∗∗∗P<0.001, ∗∗∗∗P<0.0001. (N) Flow cytometry analysis of peripheral blood ILC2s in healthy donors (n=27) compared to patients with osteoporosis (n=17). T-test, ∗P<0.05. (O) Pearson correlation analysis between ILC2s and clinical samples with available BMD T-score, n=24, black indicates healthy donor, red indicates osteoporosis patients.

Article Snippet: The concentrations of IL-10 and CGRP in cultured ILC2 supernatants were measured using mouse IL-10 ELISA Kit (Biolegend) and CGRP ELISA kit (Boster), according to the manufacturer’s instruction.

Techniques: Staining, Immunohistochemistry, Flow Cytometry, RNA Sequencing, Purification, Quantitative Proteomics, Control

Journal: Journal of Pharmaceutical Analysis

Article Title: Luteolin attenuates RA-associated chronic pain by targeting the LDHA/H3K9la/NFATC2 axis to suppress Th17 cell differentiation and central infiltration

doi: 10.1016/j.jpha.2025.101373

Figure Lengend Snippet: Luteolin (LUT) alleviates collagen-induced arthritis (CIA)-associated chronic pain by reversing central sensitization. (A) The schematic of CIA model establishment and intervention with different doses of LUT. (B) Mechanical pain threshold in each group ( n = 8 per group). (C) Thermal withdrawal latency in each group ( n = 8 per group). (D) Immunofluorescence was used to detect the expression of cFos proto-oncogene (cFos) and calcitonin gene-related peptide (CGRP) in the spinal dorsal horn (SDH) of mice across groups. Specifically, c-Fos expression was quantified by counting positive cells per mm 2 , while CGRP levels were assessed based on fluorescence intensity ( n = 4 per group). ∗ P < 0.05 and ∗∗ P < 0.01, compared with control group; # P < 0.05 and ## P < 0.01, compared with CIA model group, by repeated-measures one-way analysis of variance (ANOVA) or two-way ANOVA followed by post hoc Dunnett's multiple comparisons test. i.g. q.d.: intragastric administration once daily; DAPI: 4′,6-diamidino-2-phenylindole.

Article Snippet: : PTM-1419RM, PTM-1406RM, and PTM-1413RM; PTM Bio Inc.), rabbit anti-histone H3 (Cat. No.: ab1791; Abcam), mouse anti-CD68 (Cat. No.: sc-20060; Santa Cruz Biotechnology), rabbit anti-cFos proto-oncogene (cFos) antibody (Cat. No.: ab222699; Abcam), rabbit anti-calcitonin gene-related peptide (CGRP) antibody (Cat. No.: 14959; Cell Signaling Technology, Inc.), rabbit anti-IL-1β antibody (Cat. No.: 12242; Cell Signaling Technology, Inc.), rabbit anti-IL-6 antibody (Cat. No.: 12912; Cell Signaling Technology, Inc.), rabbit anti-TNF-α antibody (Cat. No.: 11948; Cell Signaling Technology, Inc.), rabbit anti-NFATC2 antibody (Cat. No.: 5861; Cell Signaling Technology, Inc.), rabbit anti-CD68 (Cat. No.: 97778; Cell Signaling Technology, Inc.), rabbit anti-CD40 (Cat. No.: 86165; Cell Signaling Technology, Inc.), mouse anti-NFATC2 antibody (Cat. No.: sc-7296; Santa Cruz Biotechnology), mouse anti-PRKCE antibody (Cat. No.: sc-1681; Santa Cruz Biotechnology), mouse anti-CCR6 antibody (Cat. No.: MAB590; Bio-Techne, Minneapolis, MN, USA), rabbit anti-CCL20 antibody (Cat. No.: ab9829; Abcam), rabbit anti-β-actin monoclonal antibody (Cat. No.: 4970; Cell Signaling Technology, Inc.), goat anti-rabbit IgG heavy and light chains (H&L) (Alexa Fluor® 488) (Cat. No.: ab150077; Abcam), and goat anti-mouse IgG H&L (Alexa Fluor® 647) (Cat. No.: ab150115; Abcam).

Techniques: Immunofluorescence, Expressing, Fluorescence, Control